{
    "clinical_study": {
        "@rank": "65657", 
        "brief_summary": {
            "textblock": "To assess the feasibility of using culture and staining techniques to quantify tissue\n      Mycobacterium avium Complex (MAC) burden in bone marrow. To correlate and compare changes in\n      MAC bone marrow burden with quantitative MAC blood culture results at baseline and after 4\n      and 8 weeks of treatment.\n\n      MAC is easiest to detect in the blood, although doctors generally believe that MAC in blood\n      is just \"spill-over\" from infection of other parts of the body. Traditionally, studies of\n      potential treatments for MAC focus only on MAC changes in the blood. This study compares MAC\n      changes in blood to those in bone marrow, which is another tissue where MAC is often found."
        }, 
        "brief_title": "Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients", 
        "completion_date": {
            "#text": "June 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Mycobacterium Avium-intracellulare Infection", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Mycobacterium Infections", 
                "Mycobacterium avium-intracellulare Infection"
            ]
        }, 
        "detailed_description": {
            "textblock": "MAC is easiest to detect in the blood, although doctors generally believe that MAC in blood\n      is just \"spill-over\" from infection of other parts of the body. Traditionally, studies of\n      potential treatments for MAC focus only on MAC changes in the blood. This study compares MAC\n      changes in blood to those in bone marrow, which is another tissue where MAC is often found.\n\n      Patients receive both clarithromycin and ethambutol for 48 weeks; those who become\n      intolerant to the study drugs may receive suggested substitute drugs (azithromycin and\n      rifabutin). Patients receive a bone marrow biopsy at baseline and at either 4 or 8 weeks.\n      Patients are evaluated at weeks 1, 2, 4, 6, 8, 12, 24, 36, and 48."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Any antiretroviral therapy that is approved or is available through an FDA-sanctioned\n             treatment IND or treatment protocol.\n\n          -  Primary or secondary PCP prophylaxis with TMP/SMX, dapsone, or aerosolized\n             pentamidine, as well as approved therapies for other AIDS-related opportunistic\n             infections not otherwise excluded.\n\n          -  Erythromycin, interferon-alpha, and supportive care for any therapy-related\n             toxicities as necessary.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Confirmed MAC bacteremia.\n\n          -  Consent of parent or guardian if less than 18 years of age.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  MAC inhibitors, including aminoglycosides, quinolones, clofazimine, azithromycin\n             (except when administered as a substitute drug), and rifamycins, during the first 24\n             weeks of the study.\n\n          -  Immunomodulators (including colony-stimulating cytokines such as GM-CSF and G-CSF)\n             other than those that are specifically allowed.\n\n          -  Steroids in excess of physiologic replacement doses.\n\n          -  Cytotoxic chemotherapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of treatment-limiting intolerance or hypersensitivity to the study drugs or\n             other macrolides.\n\n          -  Changes on chest radiograph within 7 days prior to study entry, that are consistent\n             with acute Pneumocystis carinii pneumonia, pulmonary tuberculosis, or other acute\n             respiratory infection.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Clarithromycin, azithromycin, or ethambutol for more than 10 consecutive days within\n             the 8 weeks prior to study entry OR between the time an initial AFB positive blood\n             sample was collected and study entry.\n\n          -  Cytokines (other than erythropoietin and interferon-alpha) within 8 weeks prior to\n             study entry.\n\n          -  Steroids within 8 weeks prior to study entry.\n\n          -  Cytotoxic chemotherapy within 8 weeks prior to study entry.\n\n          -  Acute therapy for an AIDS-related opportunistic infection or malignancy, or other\n             acute medical illness or infection within 4 weeks prior to study entry.\n\n          -  Rifabutin monotherapy if initiated for MAC prophylaxis between the time an initial\n             AFB positive blood sample was collected and study entry.\n\n          -  Aminoglycosides, quinolones, clofazimine, or rifamycins IF ADMINISTERED IN ANY\n             COMBINATION within 7 days prior to study entry OR between the time an initial AFB\n             positive blood sample was collected and study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001039", 
            "org_study_id": "DATRI 007", 
            "secondary_id": "11739"
        }, 
        "intervention": [
            {
                "intervention_name": "Ethambutol hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Clarithromycin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethambutol", 
                "Clarithromycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "Mycobacterium avium-intracellulare Infection", 
            "Drug Therapy, Combination", 
            "Ethambutol", 
            "Acquired Immunodeficiency Syndrome", 
            "Clarithromycin"
        ], 
        "lastchanged_date": "October 29, 2012", 
        "link": {
            "description": "Click here for more information about Clarithromycin", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=99"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "Univ of Arizona / Health Science Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Univ of Maryland at Baltimore"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camden", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08103"
                    }, 
                    "name": "UMDNJ - New Jersey Med School / Cooper Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "122083479"
                    }, 
                    "name": "Albany Med College / Division of HIV Medicine A158"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "117948153"
                    }, 
                    "name": "SUNY / Health Sciences Ctr at Stony Brook"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Portland Veterans Adm Med Ctr / Rsch & Education Grp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75235"
                    }, 
                    "name": "Univ of Texas Southwestern Med Ctr of Dallas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23219"
                    }, 
                    "name": "Richmond AIDS Consortium"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "The Effect of Therapy on the Tissue Burden of Disseminated MAC Infection as Measured by Quantitative Bone Marrow Culture and Correlation With Quantitative Blood Culture in HIV-Infected Patients", 
        "overall_official": [
            {
                "last_name": "Hafner R", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Drusano G", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {
        "Albany Med College / Division of HIV Medicine A158": "42.653 -73.756", 
        "Portland Veterans Adm Med Ctr / Rsch & Education Grp": "45.523 -122.676", 
        "Richmond AIDS Consortium": "37.541 -77.436", 
        "SUNY / Health Sciences Ctr at Stony Brook": "40.926 -73.141", 
        "UMDNJ - New Jersey Med School / Cooper Hosp": "39.926 -75.12", 
        "Univ of Arizona / Health Science Ctr": "32.222 -110.926", 
        "Univ of Maryland at Baltimore": "39.29 -76.612", 
        "Univ of Texas Southwestern Med Ctr of Dallas": "32.803 -96.77"
    }
}